Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

This study found that among patients with alopecia areata treated with the JAK inhibitor tofacitinib, 34% achieved complete regrowth of eyebrows and 39% achieved complete regrowth of eyelashes, highlighting differences in treatment responses across hair-bearing sites.

This study found that among patients with eyelash alopecia areata, 40% experienced complete regrowth of lashes, with a mean time to regrowth of 28 months.

This article discusses various periocular conditions like madarosis, milphosis, trichomegaly, and dermatochalasis, and highlights their potential link to underlying local and systemic diseases, but reports no new clinical findings.

This study reports a good correlation between the curvature of human eyelashes and the displacement of the neutral axis, influenced by the non-uniform thickness of the outer cuticle layer.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

This review provides an updated overview of the symptomatology, diagnosis, trichoscopy findings, and treatment options for eyebrow and eyelash alopecia, but it reports no new experimental results.

This study found that the Brigham Eyelash Tool for Alopecia (BELA) is a reliable measure for assessing eyelash loss in alopecia areata patients, demonstrating high inter- and intrarater reliability.

A woman developed rare, unexplained curly hair on her scalp and eyelashes.

Latanoprost eye drops caused excessive hair growth and eyelash whitening in a woman.

This case report describes a unique instance where a 9-year-old boy's eyelash trichotillomania was triggered by anxiety about nocturnal enuresis, which was resolved through discussions with family, teachers, and counselors.

This report describes a rare case of acquired eyelash trichomegaly in a 16-year-old female with systemic lupus erythematosus, accompanied by diffuse hair loss and "lupus hairs" on the scalp.

Malnutrition can cause unusual eyelash growth and hair loss.

This study observed that postburn hair transplants, using follicular unit micro grafting, can effectively restore facial hair and scalp regions, with eyebrow and mustache restoration yielding the highest patient satisfaction.

Eyelash loss can be a sign of thyroid problems.

This study found that full-thickness eyelid excision typically does not affect the number of eyelashes postoperatively, suggesting an increase in the growth phase of remaining follicles.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

The technique effectively makes Asian eyelashes look fuller and more natural.

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

This study found that applying 0.005% latanoprost topically to eyelashes significantly increased their length and darkened their color in healthy volunteers over three months, without causing any side effects or changes in intraocular pressure compared to a placebo.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

This systematic review identified that surgical treatments show a positive response for eyebrow and eyelash leukotrichia, while topical tofacitinib appears promising but requires further research to confirm its efficacy.

Most men prefer keeping their eyebrows over scalp hair.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that bimatoprost eye drops increased eyelash length, thickness, pigmentation, and the number of eyelashes per follicle in rabbits, without causing inflammation.